{"filing":{"accession_number":"0001725160-26-000049","cik":"0001725160","ticker":"ZNTL","company_name":"Zentalis Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"zntl-20260522.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/zntl-20260522.htm"},"events":[{"id":8880,"run_id":7794,"accession_number":"0001725160-26-000049","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Shannon Campbell as a Class I director effective May 22, 2026, with the Board expanding from six to seven members. While the disclosure includes compensatory details (annual retainer of $45,000, committee fee of $7,500, and an initial RSU grant of 114,200 shares), the principal action is the director appointment itself, making exec_appointment the most salient classification. Director appointments are material to investors as they affect board composition and governance.","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":2094,"accession_number":"0001725160-26-000049","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Shannon Campbell as a Class I director effective May 22, 2026, with the Board expanding from six to seven members. While the disclosure includes compensatory details (annual retainer of $45,000, committee fee of $7,500, and an initial RSU grant of 114,200 shares), the principal action is the director appointment itself, making exec_appointment the most salient classification. Director appointments are material to investors as they affect board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:40:45.841620+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2094,"accession_number":"0001725160-26-000049","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Shannon Campbell as a Class I director effective May 22, 2026, with the Board expanding from six to seven members. While the disclosure includes compensatory details (annual retainer of $45,000, committee fee of $7,500, and an initial RSU grant of 114,200 shares), the principal action is the director appointment itself, making exec_appointment the most salient classification. Director appointments are material to investors as they affect board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:40:45.841620+00:00","company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","filing_date":"2026-05-27"}]}